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Introduction: Rivaroxaban, a new oral anticoagulant, is currently licensed for use in patients undergoing
orthopedic surgery. It is more efficacious than other anticoagulants such as low molecular weight heparin and does
not require daily monitoring. It has also been shown to be efficacious in patients with venous thromboembolism
and acute coronary syndrome. Although hemorrhage is a known side effect of this new anticoagulant, we could
find no case reports in the literature of patients suffering severe hemorrhage whilst taking rivaroxaban. Thus, we
describe the first case of potentially fatal hemorrhage in a patient taking rivaroxaban.
Case presentation: We report the case of a 58-year-old Caucasian man with acute-onset severe per rectal bleeding
who had undergone total hip arthroplasty four weeks prior to the onset of symptoms and was taking rivaroxaban
in the postoperative period. Rivaroxaban was discontinued immediately but, having required nine units of packed
red blood cells in a peripheral hospital due to a rapidly decreasing hemoglobin level, our patient was transferred to
our tertiary referral center where he required a further eight units of packed red blood cells over a 48-hour period
to manage his ongoing hemorrhage and maintain hemodynamic stability. No source of bleeding was found on
computed tomography angiography and our patient’s condition improved over the following 48 hours with
cessation of the hemorrhage. Our patient was discharged home well several days later. A follow-up colonoscopy
one week after his discharge was normal.
Conclusion: Although advantageous with regard to its oral availability and ongoing use without the need for daily
monitoring, rivaroxaban does not come without rare but severe side effects. When severe per rectal bleeding
occurs in a patient taking rivaroxaban, discontinuation of the offending agent and aggressive hematological
replacement are the mainstays of treatment, especially when no source of bleeding can be found. This case, as the
first to describe severe hemorrhage and rivaroxaban, serves as a reminder to those prescribing the medicine that
they must inform the patient of the risk of such a serious side effect and the need for urgent medical attention if it
occurs.* Correspondence: mickyboland@gmail.com
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The new anticoagulant rivaroxaban, introduced to the
Irish Health System over three years ago, was the first in a
new line of exciting oral anticoagulant agents. Working by
inhibiting Factor Xa, rivaroxaban stops the formation of
thrombin as the extrinsic and intrinsic pathways of the co-
agulation cascade converge. As a therapeutic agent, it
boasts good pharmacokinetic qualities but the outstanding
advantage over competing anticoagulants is that there is
no need for routine coagulation monitoring and subse-
quent dose adjustments. Currently, rivaroxaban is used
clinically after total hip arthroplasty and knee replacement
surgery. The recent RECORD 1–4 Trials found that a
once daily oral dose of rivaroxaban was more effective for
extended prophylaxis than a once daily dose of subcutane-
ous enoxaparin in patients undergoing the surgeries men-
tioned above, with the two drugs having similar safety
profiles. However, the main side effect associated with this
new drug remains severe hemorrhage.
We describe a severe per rectum (PR) bleed in our pa-
tient who had undergone total hip arthroplasty (THA)
four weeks prior to the onset of symptoms and had been
taking rivaroxaban postoperatively. We focus on the rare
but very serious side effect of major bleeding in a patient
taking rivaroxaban, the management of this side effect
and the considerations that need to be taken when start-
ing a patient on this new anticoagulant. Most notably,
no previous cases of severe hemorrhage associated with
the use of rivaroxaban could be found in the literature
and so we describe this side serious effect in a case re-
port for the first time.
Case presentation
The case involves a 58-year-old Caucasian man who pre-
sented to a regional hospital with a 24-hour history of
severe PR bleeding. Our patient described the bleeding
as being acute in onset, bright red with clots and asso-
ciated with mild left iliac fossa pain. He had no other
gastrointestinal symptoms prior to the bleed and had no
history of colorectal disease. Of note, he had undergone
a THA 31 days prior to his transfer from the regional
hospital to our tertiary referral center and was taking
oral rivaroxaban as a prophylactic anticoagulant in the
postoperative period at a dose of 10 mg once daily. He
was on no other medications and had no history of renal
disease.
On arrival at the regional center, our patient had
hemodynamic stability but his PR bleeding continued
with multiple episodes involving an average of 250 to
500 mL in volume. His hemoglobin (Hb) level dropped
from 12.0 g/dL on admission to 10.3 g/dL and subse-
quently to 7.4 g/dL over a 24-hour period. His coagula-
tion profile and platelet levels were normal as was his
renal function. An abdominal computed tomographyscan revealed uncomplicated diverticular disease but no
other abnormalities. Upper gastrointestinal endoscopy
was also performed, which showed very mild gastritis
but no source of hemorrhage. In the 24 hours between
admission and transfer to our tertiary referral center, he
received a total of nine units of packed red blood cells
(PRBCs) in order to maintain hemodynamic stability.
Following transfer to our tertiary referral center, our pa-
tient had ongoing bleeding but remained hemodynamically
stable. His vitals were as follows: heart rate, 98 beats/
minute; blood pressure (BP), 134/71 mmHg; respiratory
rate, 20 breaths/minute; oxygen saturation level, 98% on
room air; and temperature, 36.0°C. On examination, he
was pale but alert and chatty. His abdomen was soft with
some mild tenderness in the left iliac fossa and there were
no palpable masses, no evidence of organomegaly and
bowel sounds were present. A PR examination was posi-
tive for fresh blood. His respiratory and cardiovascular
examinations were both normal. His Hb level on admis-
sion was 8.3 g/dl (as shown in Table 1). Our patient was
kept strictly nil by mouth and commenced on eight hourly
intravenous fluids. A group and cross-match was taken
with four units of PRBCs on standby. He was to have re-
peat Hb levels taken if further hemorrhage occurred and
his hemodynamic parameters were observed every two
hours. After a further bleed overnight, he received one
unit of PRBCs.
During the next 15 hours, our patient had a further
two episodes of fresh blood PR whilst receiving three
units of PRBCs. After the second episode his Hb level
was 8.5 g/dL and he was prescribed a further two units
of PRBCs as well as being commenced on an intravenous
proton pump inhibitor. His BP subsequently dropped to
90/57 mmHg and his intravenous fluid regime was
increased to 1 L every four hours with orders that he also
receive Gelofusine (a succinylated gelatin solution) if his
BP dropped again. He had four further episodes of bleed-
ing over the following six hours and received two more
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units since his arrival to our tertiary referral center 24 hours
earlier and 17 units in total since his presentation.
Due to the increasing frequency of these hemorrhagic
episodes, our patient underwent emergency computed
tomography mesenteric angiography. A consultant inter-
ventional radiologist could identify no obvious source of
bleeding but ordered that our patient be returned immedi-
ately to the interventional radiology suite for embolization
if further episodes of fresh blood PR occurred. His Hb
level at this time was 11.4 g/dL and our patient was
hemodynamically stable.
Over the next four days, our patient improved signifi-
cantly with no further episodes of PR bleeding. He
resumed a normal diet after three days and was dis-
charged home well with a Hb level on discharge of
10.4 g/dL. His renal function remained within normal
limits throughout his hospital stay.
Our patient returned six days later, having experienced
no further symptoms, and underwent a colonoscopy that
was entirely normal. When he was seen again six weeks
later in the outpatient clinic; he was asymptomatic and
reported feeling great. He was subsequently discharged
from our service.
Discussion
Rivaroxaban is an oral anticoagulant that works by dir-
ectly inhibiting Factor Xa and so interrupting both the
intrinsic and extrinsic pathway of the coagulation cas-
cade and subsequent thrombus formation. It is the first
orally active direct Factor Xa inhibitor and was granted
marketing authorization in 2008 by both the European
Commission and Health Canada for the prevention of
venous thromboembolism in patients who have under-
gone elective total hip replacement and total knee re-
placement surgery. Rivaroxaban’s authorization comes as
a result of the recent RECORD 1–4 Trials, which looked
at its efficacy versus subcutaneous enoxaparin as a
thromboprophylaxis in patients undergoing THA and
total knee arthroplasty [1-4]. In the RECORD 1 trial, a
randomized double-blinded study, 4,518 patients were
assigned to receive 10 mg daily of oral rivaroxaban im-
mediately after THA or 40 mg once daily of subcutane-
ous heparin beginning the same evening after THA [1].
The primary efficacy outcome was the composite of
deep venous thrombosis, nonfatal pulmonary embolism
or death after 36 days and, significantly, the major safety
outcome was major bleeding. The primary efficacy out-
come occurred in 18 of 1,595 patients (1.1%) in the riv-
aroxaban group and in 58 of 1,558 patients (3.7%) in the
enoxaparin group (absolute risk reduction, 2.6%; 95%
confidence interval, 1.5 to 3.7; P< 0.001). Major bleed-
ing occurred in 6 of 2,209 patients (0.3%) in the rivarox-
aban group and in 2 of 2,224 patients (0.1%) in theenoxaparin group (P= 0.18). The authors concluded that a
once daily oral dose of rivaroxaban was more effective for
extended thromboprophylaxis than a once daily subcuta-
neous dose of enoxaparin in patients undergoing elective
THA, with the two drugs having similar safety profiles.
The manufacturers recommend that rivaroxaban only
needs be taken for 35 days postoperatively, after which the
risk of such a thrombotic event decreases hugely. Al-
though six cases of major bleeding were reported in the
RECORD 1 trial, we could find no available case reports
in the literature regarding this side effect.
The circumstances of our patient’s case demonstrated
very clearly both the obvious advantages and yet the se-
vere disadvantages of rivaroxaban. Upon its formulation,
the immediate appeal of this drug was three-fold. First, it
was more efficacious in preventing deep venous throm-
bosis or pulmonary embolisms compared to other antic-
oagulants, as shown in the RECORD trials. Second, it
could be taken orally, negating the need for daily subcuta-
neous injections that patients experience if taking heparin
or a low-molecular-weight heparin, most notably in the
immediate days after surgery. Third, and perhaps most
significantly from a socioeconomic perspective, regular
visits to general practitioners or outpatient clinics for
international normalized ratio monitoring when taking
warfarin are also unnecessary when taking rivaroxaban.
Interestingly, rivaroxaban is the first oral Factor Xa inhibi-
tor licensed for this purpose in Ireland. It will most likely
set a trend for a class of oral anticoagulants that will see
the end of subcutaneous anticoagulation as well as oral
anticoagulants that require continuous blood level moni-
toring. Although only currently licensed for orthopedic
surgery, more recent studies have shown that rivaroxaban
is as effective as enoxaparin when treating symptomatic
venous thromboembolism. In addition, a Phase III study
of low-dose rivaroxaban in patients with acute coronary
syndrome is also underway after a recent Phase II study
showed that it may reduce major ischemic events [5,6].
In this case, the fact that our patient had no history of
hemorrhage in the past and that the organ and asso-
ciated system involved, the rectum and gastrointestinal
tract, had never caused him medical problems prior to
this makes the magnitude of the PR bleeding more note-
worthy. The absence of any risk factors would have
placed him in a low-risk category for side effects. The
RECORD 1 trial found reports of major bleeds in only
six patients and this case demonstrates that these side
effects, though rare, do occur in supposedly low-risk
patients, with serious and potentially fatal complications.
The treatment of such a severe side effect includes
transfusion with PRBCs based on regularly observed Hb
levels. One could consider the role of radiological
embolization if a source is found but this was not an op-
tion in our case. The most important learning point,
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quickly as possible. This relies on a detailed history with
specific focus on recent pharmacological treatments.
Rivaroxaban has a mean terminal half-life of seven to
eleven hours, which should be taken into account along
with other medications that the patient is taking, such as
antimycotics or human immunodeficiency virus protease
inhibitors, which can potentiate bleeding. Once the
agent is discontinued, bridging the patient through the
period of hemorrhage safely is the primary goal. The
lack of any obvious antidote to reverse the effects of the
drug is an aspect that needs further research. Early stud-
ies have shown that prothrombin complex concentrate
may be useful in reversing the effects of rivaroxaban [7].
Other possible measures include the use of recombinant
Factor VIIa to reduce bleeding or the use of activated
charcoal to reduce absorption in cases of overdose.
Conclusion
This case outlines clearly, and for the first time in the litera-
ture, the rare but serious risk of hemorrhage associated
with rivaroxaban. Prescribing orthopedic specialists should
take care in providing information regarding the risk of
bleeding to patients commencing the medication and in-
form these patients that urgent medical attention is needed
if such a side effect occurs. The efficacy and ease of use
associated with this new anticoagulant means that its use is
likely to increase across multiple medical specialties, mak-
ing this case important for a wide range of medical profes-
sionals. This case also outlines how such a side effect is
managed effectively and that immediate discontinuation of
rivaroxaban is a vital step in dealing with hemorrhage. This
case has not altered the use of rivaroxaban in our health fa-
cility but has drawn attention to a serious side effect of the
drug.
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